Rest In Peace SPACs And Pseudo-Platforms: What Lies Ahead For Biotechs Going Public In 2023

Panelists at the BIO CEO and Investor Conference foresee some changes coming as biotech investors become more judicious about where they park their money.

• Source: Shutterstock

What kinds of biotech companies are able launch offerings on the public markets and what means they use to do so are likely to see some significant changes in 2023 as investors become more judicious about where they park their money. Notably, mergers with special purpose acquisition corporations (SPACs), which became a popular means of going public a few years ago, will likely dry up, while it’s also unlikely that companies will have as easy a time going public with just one product as they did in prior years.

Those were some of the key take-home messages of a panel discussion about the outlook for initial public offerings and...

More from Financing

More from Business